RxDoctor Payments Data

Christopher Morriss, MD

Family Medicine · Las Cruces, NMNPI 1538699947

Payments from drug & device makers

$792in general payments, 2019–2025

Across 44 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$170
  • Lilly USA, LLC$132
  • Novo Nordisk$118
  • Pfizer$106
  • GSK$55
  • Xeris Pharmaceuticals, Inc.$45
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$792 in reported general payments places this provider in the 75th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$76,744
Medicare patients
162
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$92,133
TrulicityDulaglutide74$87,169
OzempicSemaglutide76$86,209
FarxigaDapagliflozin Propanediol54$47,735
JanuviaSitagliptin Phosphate22$36,835
MounjaroTirzepatide24$26,383
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$22,194
Tresiba Flextouch U-100Insulin Degludec39$20,874
RybelsusSemaglutide11$20,816
EliquisApixaban14$19,347
XareltoRivaroxaban11$15,458
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,258
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,625
Novolog FlexpenInsulin Aspart22$4,638
Levemir FlexpenInsulin Detemir22$3,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$132$113,55198 claims
Novo NordiskOzempic, Rybelsus$118$107,02487 claims
Boehringer IngelheimJardiance, Stiolto Respimat$22$100,39068 claims
AstraZenecaFarxiga$170$47,73554 claims
PfizerEliquis$106$19,34714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →